TY - JOUR
T1 - Radiopharmaceuticals for Neuroendocrine Tumors
AU - Chin, Re I.
AU - Wu, Francis S.
AU - Menda, Yusuf
AU - Kim, Hyun
N1 - Funding Information:
Funding: Yusuf Menda: NIH. Conflicts of Interest: Re-I Chin (none), Francis Wu (none), Yusuf Menda (Research Grant- Advanced Accelerator Applications), Hyun Kim (none).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of 177Lu-DOTATATE (Lutathera) in the treatment of somatostatin receptor-positive gastroenteropancreatic NETs. Similarly, data from the multicenter, phase II Study IB12B led to the approval of meta-[131I]Iodo-Benzyl-Guanidine (I31I-MIBG) for treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. With the clinical approval of these novel radiopharmaceuticals for managing select patients with NETs, additional studies are needed to refine patient selection, predict and assess therapy response, and optimize radiopharmaceutical delivery and clinical outcomes.
AB - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of 177Lu-DOTATATE (Lutathera) in the treatment of somatostatin receptor-positive gastroenteropancreatic NETs. Similarly, data from the multicenter, phase II Study IB12B led to the approval of meta-[131I]Iodo-Benzyl-Guanidine (I31I-MIBG) for treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. With the clinical approval of these novel radiopharmaceuticals for managing select patients with NETs, additional studies are needed to refine patient selection, predict and assess therapy response, and optimize radiopharmaceutical delivery and clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85089159131&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2020.07.007
DO - 10.1016/j.semradonc.2020.07.007
M3 - Review article
C2 - 33246637
AN - SCOPUS:85089159131
SN - 1053-4296
VL - 31
SP - 60
EP - 70
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 1
ER -